Mommy’s Bliss Nipple Cream Recall

Mommy’s Bliss Nipple Cream has been removed from the market because certain ingredients contained in the product could be harmful to nursing infants. On Friday, the FDA issued a warning for mothers not to use the nipple cream and to seek immediate medical care if their baby experiences problems such as respiratory distress, vomiting or diarrhea.

The recalled nipple cream was marketed by California based MOM Enterprises, Inc. to help nursing mothers soothe and heal dry or cracked nipples. Although the label specifically states that there is no need to remove the cream before nursing, the FDA indicates that two of the ingredients could pose a serious health risk. The Mommy’s Bliss Nipple Cream contains chlorphenesin and phenoxyethanol, which could depress the central nervous system, cause repiratory depression or vomiting and diarrhea, which can lead to dehydration for infants.

“The FDA is particularly concerned that nursing infants are being unwittingly exposed by their mothers to this product with dangerous side effects,” said FDA official Janet Woodcock, M.D.

Hair-Dye-Cancer-Lawsuits
Hair-Dye-Cancer-Lawsuits

Some of the symptoms of problems which could be caused by the recalled nipple cream include:

  • Vomiting
  • Diarrhea
  • Dehydration
  • Respiratory Depression (slow or shallow breathing)
  • Difficulty Waking
  • Limp Extremities
  • Decreased Strength of Grip
  • Skin Color Changes

Any users who have experienced side effects from the Mommy’s Bliss Nipple Cream have been asked to report adverse events to the FDA’s MedWatch at (800) 332-10800 or on the internet at http://www.fda.gov/medwatch/report.htm.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025.
Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case.
An Indiana woman has filed a Cartiva SCI implant lawsuit, indicating that the toe implant failed due to a defective design, resulting in the need for revision surgery and recommendations to permanently fuse her big toe.